Increased utilization of next-generation sequencing (NGS) has revealed the presence of recurrent alterations in TP53 in approximately 6–7% of patients with localized PCa and up to 50% of patients with advanced disease [9,10,11]. Here, TP53 is linked to posterior cortical atrophy.